Subscribe
taljat-david
Taljat David / Shutterstock.com
14 July 2020Biotechnology

Junshi licenses COVID-19 antibody tech from Lonza

China’s  Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm  Lonza.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
Americas
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23 July 2020   Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
Americas
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23 July 2020   Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
Americas
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23 July 2020   Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers